GSVRX
Price
$16.41
Change
+$0.08 (+0.49%)
Updated
Jun 9 closing price
Net Assets
457.1M
RMEBX
Price
$62.54
Change
+$0.38 (+0.61%)
Updated
Jun 9 closing price
Net Assets
116.64B
Interact to see
Advertisement

GSVRX vs RMEBX

Header iconGSVRX vs RMEBX Comparison
Open Charts GSVRX vs RMEBXBanner chart's image
GSVRX vs RMEBX Comparison Chart in %
View a ticker or compare two or three
VS
GSVRX vs. RMEBX commentary
Jun 10, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSVRX is a Buy and RMEBX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RMEBX has more cash in the bank: 117B vs. GSVRX (457M). RMEBX pays higher dividends than GSVRX: RMEBX (1.04) vs GSVRX (0.43). GSVRX was incepted earlier than RMEBX: GSVRX (19 years) vs RMEBX (12 years). GSVRX (1.49) is less costly to investors than RMEBX (1.07). GSVRX is a more actively managed with annual turnover of: 74.00 vs. RMEBX (30.00). GSVRX has a lower initial minimum investment than RMEBX: GSVRX (0) vs RMEBX (250). RMEBX annual gain was more profitable for investors over the last year : 9.19 vs. GSVRX (7.60). RMEBX return over 5 years is better than : 32.68 vs. GSVRX (0.93).
GSVRXRMEBXGSVRX / RMEBX
Total Expense Ratio1.251.07117%
Annual Report Gross Expense Ratio1.491.07139%
Fund Existence19 years12 years-
Gain YTD13.0895.953220%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets457M117B0%
Annual Yield % from dividends0.431.0442%
Returns for 1 year7.609.1983%
Returns for 3 years19.3733.8657%
Returns for 5 years0.9332.683%
Returns for 10 years18.2489.6920%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SBFG22.890.65
+2.92%
SB Financial Group
KRO6.530.02
+0.31%
Kronos Worldwide
BOX26.54-0.01
-0.04%
BOX
MTSI358.72-3.14
-0.87%
MACOM Technology Solutions Holdings
BOLT4.62-0.10
-2.12%
Bolt Biotherapeutics Inc